Login to Your Account

Clinic Roundup

Tuesday, May 21, 2013
• Neuralstem Inc., of Rockville, Md., presented updated, favorable Phase I data from its spinal cord-derived human neural stem cell (NSI-566) trial in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig 's disease) at the neuro-diabetes special medical symposium in Bucharest, Romania.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription